

Magnitude of systolic blood pressure reduction following endovascular treatment and clinical outcomes in acute large artery occlusion stroke

Xianjun Huang ⁽¹⁾, ¹ Xianhui Ding, ¹ Hao Wang, ¹ Qiankun Cai ⁽²⁾, ² Junfeng Xu, ¹ Zibao Li, ¹ Qian Yang, ¹ Zhiming Zhou, ¹ Jie Xu^{3,4}

ABSTRACT

Background The impact of lowering systolic blood pressure (SBP) following endovascular treatment (EVT) in acute large vessel occlusion stroke (LVOS) patients remains unclear. We aimed to explore the effect of the magnitude of SBP reduction (SBPr) after EVT on outcomes in LVOS patients.

Methods We consecutively registered patients at three comprehensive stroke centres who had experienced EVT as a result of acute anterior circulation LVOS. SBPr was calculated as follows: (baseline SBP-mean SBP/baseline SBP)×100%. The 90-day modified Rankin Scale score ranging from 0 to 2 was defined as a favourable functional outcome. Based on CT scans obtained within 24 hours after procedure, symptomatic intracranial haemorrhage (sICH) was assessed according to the criteria of the European Cooperative Acute Stroke Study III. Results We enrolled 1080 patients, of which 908 (84.1%) had successful recanalisation. In the overall cohort, SBPr was correlated with lower odds of sICH (SBPr±10% as a reference. 20%-30%: OR 0.460: 95% CI: 0.245 to 0.864: p=0.016: >30%: OR 0.304: 95% CI 0.123 to 0.749: p=0.010). In patients who achieved successful reperfusion, SBPr>30% was correlated with higher odds of a poor outcome (SBPr±10% as a reference, OR 2.150; 95% CI 1.268 to 3.645; p=0.004) and SBPr has a similar tendency towards reducing the incidence of sICH. In the subgroup analyses, baseline Alberta Stroke Programme Early CT (ASPECT) score (p_{interact}=0.024) modified the effect of SBPr on the 90-day outcome.

Conclusion Among patients with EVT, a significant drop in SBP may be related to a poor functional outcome and a reduced incidence of sICH. Baseline ASPECT score may be an important interacting factor in the association of SBPr with the 90-day outcome. This study provides new insights for individualised BP management in patients with EVT.

INTRODUCTION

Currently, endovascular treatment (EVT) has become the standard of treatment for patients experiencing acute large vessel occlusion stroke (LVOS) in both anterior and posterior circulation.¹² Moreover, with the development of thrombectomy technology, the indications for EVT are gradually expanding.³⁴ However, it should be noted that more than 50% of

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Blood pressure (BP) is a crucial, potentially modifiable factor that can improve favourable neurological outcomes in patients undergoing acute reperfusion therapy. However, the optimal BP management after the endovascular treatment (EVT) is currently unknown. A meta-analysis of recent randomised clinical trials showed that aggressive post-EVT BP reduction did not provide clinical benefits and may pose risks. However, how the magnitude of BP reduction determined high or low risk of harms was unclear.

WHAT THIS STUDY ADDS

- ⇒ Significant systolic BP reduction (SBPr) after EVT was related to the worse 90-day functional outcome in patients who achieved successful recanalisation, and there was a J-shaped relationship between SBPr and the 90-day outcome.
- ⇒ There is a negative relationship between SBPr and the incidence of symptomatic intracranial haemorrhage in patients with EVT.
- \Rightarrow Baseline Alberta Stroke Programme Early CT (ASPECT) score was an important interact factor in the relationship between outcomes after EVT and SBPr.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The main strength of this study was that it provides in-depth research on the impact of BP reduction on the prognosis after EVT. Several factors need to be considered in the periprocedural BP management, such as baseline ASPECT score. Our study provides new insights for individualised BP management in patients with EVT.

patients who receive EVT have not gained functional independence despite the achievement of successful vessel recanalisation.⁵ Apart from the advancements in thrombectomy technology, improving periprocedural management may further enhance patient outcomes.

Stroke Vasc Neurol: first published as 10.1136/svn-2024-003221 on 20 August 2024. Downloaded from http://svn.bmj.com/ on May 6, 2025 by guest. Protected by copyright

To cite: Huang X, Ding X, Wang H, *et al.* Magnitude of systolic blood pressure reduction following endovascular treatment and clinical outcomes in acute large artery occlusion stroke. *Stroke & Vascular Neurology* 2024;**0**. doi:10.1136/svn-2024-003221

Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/ svn-2024-003221).

XH, XD and HW contributed equally.

Received 28 February 2024 Accepted 5 August 2024

Check for updates

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Neurology, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China

²The Department of Neurology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, FuJian, China ³Institutes of Brain Science, Wannan Medical College, Wuhu, Anhui Province, China ⁴Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Correspondence to

Dr Jie Xu; xujie@ncrcnd.org.cn

Dr Zhiming Zhou; neuro_depar@hotmail.com





Blood pressure (BP) is a crucial, potentially modifiable factor that can improve favourable neurological outcomes in patients undergoing acute reperfusion therapy.⁶ In the setting of acute ischaemic stroke, initial BP is often elevated to augment blood flow via collateral circulation to the ischaemic region.⁷ However, higher systemic BP may worsen clinical outcomes through increased risks of intracerebral haemorrhage (ICH) or cerebral oedema after successful EVT.⁸⁻¹⁰ Therefore, lowering BP following EVT has been recognised as an acceptable clinical practice, as shown by a survey conducted among StrokeNet institutions.¹¹ However, a meta-analysis of recent randomised clinical trials (RCTs) on early intensive BP management after successful reperfusion following EVT showed that aggressive post-EVT BP reduction did not provide clinical benefits and may pose risks.¹²

The Outcome in Patients Treated With Intra-Arterial Thrombectomy-Optimal Blood Pressure Control (OPTI-MAL-BP) trial¹³ showed that intensive BP management (<140 mm Hg) was associated with worse functional outcomes than conventional BP management (140-180 mm Hg) in successful EVT patients, which is consistent with the results of the Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED2/ MT).¹⁴ The BP Target in Acute Stroke to Reduce Haemorrhage After Endovascular Therapy (BP-TARGET) trial¹⁵ indicated that the intensive systolic BP (SBP) management of 100-129 mm Hg following successful recanalisation did not reduce the rate of ICH as compared with the conventional SBP management of 130-185 mm Hg. However, the level of intensive BP management in these RCTs was not unified, and how the magnitude of BP reduction determined high or low risk of harms was unclear.

In view of the former considerations, we performed an investigation to explore the effect of the magnitude of SBP reduction (SBPr) after EVT on outcomes in LVOS patients. We further analysed the association between BP drop and prognosis among different subgroups.

METHODS

Study design

We conducted a retrospective study using a multicentre registry data from three comprehensive stroke centres (Yijishan Hospital, Wannan Medical College; the Second Affiliated Hospital, Fujian Medical University; and Jinling Hospital, Nanjing University) between July 2015 and April 2023. We included patients who underwent EVT due to acute anterior circulation LVOS. Patients were excluded based on the following criteria: (1) baseline Alberta Stroke Programme Early CT (ASPECT) score within 0–2; (2) time from stroke onset to puncture (OTP)>24 hours; (3) prestroke modified Rankin Scale (mRS) score \geq 2; (4) technical failures, such as puncture failure or inability to establish pathways due to vascular tortuosity, etc; (5) multiple vessel occlusion; (6) lost to follow-up at the 90 days visit and (7) BP records less than 10 times.

Postprocedural BP parameters

BP was measured in the cath lab before EVT. Then, for the first 24 hours, we used noninvasive BP monitoring devices to measure BP every hour after EVT. According to the previous study, SBPr was calculated using the formula: (aSBP–mSBP/aSBP)×100%,¹⁶ where aSBP is the SBP measured at the cath lab before EVT, and mSBP is the average SBP during the initial 24 hours postprocedure. Additionally, data regarding the usage of antihypertensive medications have also been collected for analysis.

Clinical data collection

We documented the baseline clinical data for all of the patients, including medical history and demographics. We also included the metric of workflow, the baseline National Institutes of Health Stroke Scale (NIHSS) and ASPECT score and the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification.

The operators recorded the procedural data, including the metric of EVT, occlusion site, collateral score and recanalisation status. Occlusion site included internal carotid artery occlusion, the M1 segment of middle cerebral artery (MCA) occlusion and medium vessel occlusions (MeVO). MeVO was defined as the occlusion of MCA M2 segment or occlusion of the anterior cerebral artery.¹⁷ We used the modified Thrombolysis in Cerebral Infarction (mTICI) grading system to evaluate the recanalisation status.¹⁸ A score of 2b or 3 in mTICI indicated successful recanalisation. Collateral circulation status was evaluated by observing the backward flow of contrast in vessels within the occluded region on delayed digital subtraction angiography images. Good collaterals were characterised by more than 50% perfusion of the occluded area.¹⁹

Outcomes

Clinical outcomes were assessed using the 90-day mRS, with mRS 0–2 being defined as a favourable clinical outcome and mRS≥3 being defined as a poor outcome. According to the European Cooperative Acute Stroke Study III criteria, symptomatic intracranial haemorrhage (sICH) was characterised as any haemorrhage confirmed on CT imaging within 24 hours after thrombectomy, and accompanied by a ≥4-point increase in NIHSS score.²⁰

Statistical analysis

Results are given for continuous variables as the mean±SD or the median (IQR). We using the Mann-Whitney U test to assess continuous variables. Results are given for categorical variables as percentages. We used Fisher's exact test or the χ^2 test, as warranted, to assess categorical variables.

The effect of BP reduction on clinical outcomes was analysed by a binary logistic regression. To evaluate the magnitude and direction of change in BP, we categorised BP reduction for the logistic regression as follows: <-10%, -10% to 10% (reference), 10% to 20%, 20% to 30% and >30%. To prevent multicollinearity, we did not adjust for mean SBP or baseline BP. Regression coefficients and ORs

with two-sided 95% CIs for each of the variables included in the model were finally calculated. In order to visualise the trend, we also examined the shape of the relationship between SBPr and the 90-day functional outcome or sICH by using a regression curve of ORs (95% CI).

According to the history of hypertension, use of antihypertensive medications following EVT, baseline ASPECT score (3–5 vs 6–10), collateral circulation status, occlusion site and baseline BP (\geq 140 mm Hg vs <140 mm Hg). we conducted subgroup analyses. We adjusted the regression models using an interaction term between BP reduction and the subgroup to stratify the significance of the tested subgroups.

Finally, a sensitivity analysis was performed using the BP in the emergency room as the baseline BP. We set a twotailed value of p<0.05 to denote statistical significance. All statistical analyses were computed by using SPSS V.25 (IBM) and R-studio (V.4.0.4, R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

During the study period, a total of 1323 patients receiving EVT treatment were registered. Of this total, 1080 patients were analysed in this study. The flow chart of inclusion of the study population is shown in figure 1. The median



Figure 1 Study population. ACA, anterior cerebral artery; ASPECT, Alberta Stroke Programme Early CT; BP, blood pressure; CSCs, comprehensive stroke centres; EVT, endovascular treatment; LVOS, large vessel occlusion stroke; mRS, modified Rankin score; OTP, symptoms onset to groin puncture time.

age was 70 (IQR 60–76) years and 630 (58.3%) were men. The median baseline NIHSS score was 15 (12–18), the median baseline ASPECT was 9 (7–10), the median OTP was 290 (220–360) min, 908 (84.1%) patients achieved successful recanalisation (TICI scores of 2b or 3), 534 (49.4%) patients achieved 90-day mRS 0–2 and 86 patients (7.9%) developed sICH.

Relationship between outcomes and BP reduction

In the overall cohort, the median SBP reduction (SBPr) was 17.3% (8.2%, 25.9%) and the diastolic BP reduction (DBPr) was 15.9% (5.8%, 25%). SBPr and DBPr were not significantly different between the 90 d mRS 0–2 group and the 90 d mRS 3–6 group. However, compared with patients with sICH, patients with non-sICH had higher SBPr (17.5% vs 11.7%, p=0.001). Online supplemental table S1 lists the baseline characteristics and demographics of the overall cohort. After adjusting for potential confounders, SBPr>20% was associated with lower odds of sICH (SBPr±10% as a reference, 20%–30%: OR 0.460; 95% CI 0.245 to 0.864; p=0.016; >30%: OR 0.304; 95% CI 0.123 to 0.749; p=0.010, online supplemental table S2).

In patients with successful reperfusion, patients with poor outcomes had a significant reduction in SBP (19.2%)vs 17.5%, p=0.029). Patients with non-sICH also had a significant reduction in SBP (18.3% vs 14.5%, p=0.013). The baseline characteristics and patient demographics for those who had successful reperfusion are shown in table 1. In the multivariate analysis (table 2), SBPr>30% was associated with higher odds of a poor outcome (SBPr±10% as a reference, OR 2.150; 95% CI 1.268 to 3.645; p=0.004). Figure 2A illustrates a J-shaped relationship between SBPr and poor outcomes. In addition, SBPr has a similar tendency towards reducing the incidence of sICH, however, a significant statistical difference was not achieved. We observed a linear relationship between SBPr and sICH (figure 2B). The distribution of the 90-day mRS scores and the incidence of sICH in the different SBPr categories is shown in figure 3.

Additionally, in patients with unsuccessful reperfusion, no significant differences were found in SBPr, regardless of in the subgroup for 90d mRS or sICH (online supplemental table S3).

Relationship between outcomes and BP reduction in the subgroup analysis

Figure 4 illustrates the subgroup analyses for patients who experienced successful reperfusion. We found that a large magnitude of SBPr (SBPr>30%) was correlated with significantly higher odds of poor outcome than minimal SBPr ($\pm 10\%$). However, the baseline ASPECT score ($p_{interact}=0.024$) modified the effect of SBPr on the 90-day outcome.

Although a tendency of SBPr associated with lower odds of sICH was found in most subgroups, a significant statistical difference was found only in those patients who had poor collateral circulation. There may be an interaction between collateral circulation status and SBPr for the incidence of sICH ($p_{interact}$ =0.092). In addition, there may be an interaction between baseline BP and SBPr for the incidence of sICH ($p_{interact}$ =0.031), however, a significant statistical difference was not achieved in the subgroup analyses.

Sensitivity analysis

While SBP in the emergency room was defined as aSBP (n=731), we also found that SBPr after EVT was related to the worse functional outcomes at 90 days in patients with successful reperfusion, and SBPr was associated with lower odds of sICH (online supplemental table S4).

DISCUSSION

In the current study, three main findings were as follows: (1) significant SBPr after EVT was related to the worse 90-day functional outcome in patients who achieved successful recanalisation, and there was a J-shaped relationship between SBPr and the 90-day outcome; (2) there is a negative relationship between SBPr and the incidence of sICH in patients with EVT and (3) baseline ASPECT score was an important interact factor in the relationship between outcomes after EVT and SBPr.

In theory, persistently elevated BP after successful EVT may have worse clinical outcomes by increasing the risk of cerebral oedema and intracerebral haemorrhage. Moreover, previous retrospective studies showed that SBPr in the first 24 hours after successful EVT was inversely associated with poor outcomes.^{16 21} However, recent RCTs have reached the opposite conclusion, which was that intensive BP management was associated with poorer functional outcomes than conventional BP management.¹³⁻¹⁵ An important issue was how the magnitude of BP reduction determined high or low risk of harms was unclear. In this study, we found that a large magnitude of SBPr after EVT was related to a poorer functional outcome at 90 days in patients who achieved successful recanalisation, and this relationship was J-shaped. Nevertheless, these results seem to contradict that of the Blood Pressure Management After Endovascular Therapy for Acute Ischaemic Stroke (BEST-II) trial and previous observational studies.^{16 22 23} The BEST-II trial was a phase II study to evaluate the futility of lower SBP targets after EVT (<140mm Hg or 160mm Hg) compared with a higher target ($\leq 180 \text{ mm Hg}$).²³ However, this study did not show that lower SBP targets of less than 140 mm Hg and less than 160mm Hg meet prespecified criteria for futility compared with a target of 180 mm Hg or less.

Several reasons could explain the above conflicting results. First, the intensive BP management in the previous RCTs did not consider baseline BP. In our study, the SBPr is an interesting clinical parameter that taken into account the patient's baseline BP and attempts to reduce the intragroup variability of patients with widely varied baseline BP. Second, the selection of different baseline BPs also affects the magnitude of BP reduction.

Table 1 Baseline characteristics at	nd demographics	in patients who had	d successi	ful reperfusion			
	mRS 0–2 n=494	mRS 3–6 n=414	P value	sICH* n=56	Non-sICH n=847	P value	
Age, median (IQR), year	67 (57–74)	72 (64–78)	<0.001	69 (60–77)	69 (60–76)	0.983	
Male, n (%)	316 (64)	227 (54.8)	0.005	36 (64.3)	503 (59.4)	0.469	
Hypertension	303 (61.3)	288 (69.6)	0.010	34 (60.7)	554 (65.4)	0.475	
Diabetes mellitus	66 (13.4)	93 (22.5)	< 0.001	12 (21.4)	147 (17.4)	0.438	
Clinical characteristics, median (IQF	R)						
Baseline NIHSS scores	13 (11–17)	16 (13–20)	< 0.001	16 (13–19)	14 (12–18)	0.010	
Baseline ASPECT scores	9 (8–10)	8 (6–9)	< 0.001	8 (7–9)	9 (8–10)	0.008	
IVT, n (%)	91 (18.4)	67 (16.2)	0.376	14 (25)	144 (17)	0.127	
Blood pressure parameters, median	I (IQR)						
Baseline SBP, mm Hg	150 (131–164)	154 (139–170)	< 0.001	149 (130–160)	150 (135–168)	0.140	
Baseline DBP, mm Hg	83 (74–92)	84 (75–95)	0.392	84 (74–92)	83 (74–93)	0.562	
Mean SBP (24 hours), mm Hg	121 (115–128)	123 (117–130)	0.001	126 (116–133)	122 (116–129)	0.073	
Mean DBP (24 hours), mm Hg	70 (65–75)	69 (63–75)	0.181	69 (65–78)	70 (64–75)	0.440	
SBPr, %	17.5 (8.6–25.7)	19.2 (10.9–28.1)	0.029	14.5 (2.7–20.8)	18.3 (9.9–26.7)	0.013	
DBPr, %	16 (6.2–24.2)	17.8 (7.8–27.1)	0.059	13.2 (3.9–25.1)	17.1 (7.1–26)	0.132	
Continuous intravenous antihypertensive agents, n (%)	246 (49.8)	260 (62.8)	<0.001	37 (66.1)	466 (55)	0.107	
TOAST classification, n (%)			< 0.001			0.473	
LAA	164 (33.2)	106 (25.6)		13 (23.2)	257 (30.3)		
Cardioembolic	256 (51.8)	278 (67.1)		37 (66.1)	492 (58.1)		
Others	74 (15)	30 (7.2)		6 (10.7)	98 (11.6)		
Occlusion site, n (%)			< 0.001			0.786	
ICA	162 (32.8)	189 (45.7)		24 (42.9)	324 (38.3)		
MCA M1	281 (56.9)	193 (46.6)		27 (48.2)	445 (52.5)		
MeVO	51 (10.3)	32 (7.7)		5 (8.9)	78 (9.2)		
OTP, mean (IQR), min	300 (225–370)	300 (220–390)	0.486	300 (221–360)	300 (225–390)	0.849	
OTR, mean (IQR), min	349 (278–438)	352 (288–470)	0.087	360 (288–440)	350 (282–455)	0.695	
Collateral score†, n (%)			< 0.001			0.008	
Poor	158 (32.1)	255 (61.7)		35 (62.5)	373 (44.2)		
Good	334 (67.9)	158 (38.3)		21 (37.5)	471 (55.8)		

*5 patients missing.

+3 patients missing.

ASPECT, Alberta Stroke Programme Early CT; DBP, diastolic blood pressure; DBPr, DBP reduction; ICA, internal carotid artery; IVT, intravenous thrombolysis; LAA, large-artery atherosclerosis; MCA, middle cerebral artery; MeVO, medium vessel occlusions; NIHSS, National Institutes of Health Stroke Scale; OTP, symptoms onset to groin puncture time; OTR, symptoms onset to reperfusion; SBP, systolic blood pressure; SBPr, SBP reduction; sICH, symptomatic intracranial haemorrhage; TOAST, the Trial of ORG 10172 in Acute Stroke Treatment.

In the post hoc analysis of the BP-TARGET trial,²² the baseline BP was the end of procedure BP. Both intraoperative procedures and anaesthesia can affect the postoperative BP.²⁴ In this study, the cath lab BP before EVT was used as the baseline BP. No patients underwent sedation or anaesthesia before the first baseline BP measurement. Third, the relationship between BP and prognosis in acute ischaemic stroke is complex. In the study, we found a J-shaped relationship between SBPr and the 90-day outcome (figure 2), which may explain that elevated SBP after successful reperfusion by EVT was harmful in most

previous retrospective studies.^{8–10} Last, the different study designs and the imbalanced patients' baseline characteristics likely contributed to the differences in the results.

The mechanism by which BP reduction leads to adverse outcomes may be that a significant BP lowering might further reduce blood flow to the oligemic zone and exacerbate ischaemic injury.²⁵ Despite successful reperfusion after EVT, patients might exhibit persistent venous postcapillary thrombosis, a phenomenon also known as no-reflow.²⁶ In this situation, the prognosis of the acute ischaemic lesion may be affected negatively by the

Table 2 Relationship of SBP reduction following successful reperfusion with outcomes										
SBPr	Incidence, n (%)	OR	95% CI	P value						
Poor outcome* (n=414)										
±10% (n=206)	80 (38.8)		Reference							
<-10% (n=32)	15 (46.9)	1.249	0.511 to 3.048	0.626						
10%–20% (n=272)	125 (46)	1.492	0.973 to 2.288	0.066						
20%-30% (n=263)	114 (43.3)	1.158	0.749 to 1.790	0.509						
>30% (n=135)	80 (59.3)	2.150	1.268 to 3.645	0.004						
sICH† (n=56)										
±10% (n=206)	17 (8.3)		Reference							
<-10% (n=32)	4 (12.5)	1.531	0.473 to 4.955	0.477						
10%–20% (n=271)	20 (7.4)	0.917	0.465 to 1.809	0.803						
20%-30% (n=260)	10 (3.8)	0.476	0.212 to 1.069	0.072						
>30% (n=134)	5 (3.7)	0.419	0.150 to 1.172	0.098						

*Adjusted for age, sex, baseline NIHSS and ASPECT, history of hypertension and diabetes mellitus, antihypertensive treatment, TOAST classification, collateral circulation and occlusion site.

†Adjusted for baseline NIHSS, ASPECT and collateral circulation.

ASPECT, Alberta Stroke Programme Early CT; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; SBPr, SBP reduction; sICH, symptomatic intracranial haemorrhage; TOAST, Trial of ORG 10172 in Acute Stroke Treatment.

intensive BP reduction even after successful EVT. Further analysis of the perfusion imaging data or using short-term imaging endpoints in the future may provide evidence for a potential mechanism leading to worse outcomes associated with BP reductions. It is worth noting that there is a significant dose–response relationship between SBPr and the 90-day outcome (figure 2). These results may contribute to the design of future research.

The negative association between SBPr and the incidence of sICH has been proven in previous studies.^{21 22} Similarly, we also found that SBPr>20% was correlated with reduced odds of sICH. In the BP-TARGET trial,¹³ an intensive SBP target of 100–129 mm Hg following successful EVT did not reduce the rates of radiographic ICH. A possible explanation was that the BP reduction was only 17% in the intensive SBP target group. Additionally, an important finding in our study was that the relationship between SBPr and sICH was mainly in patients with poor collateral circulation, which explained why, in the ENCHANTED2/MT trial, more intensive BP treatment did not decrease the incidence of sICH.¹⁴ In the ENCHANTED2/MT trial, the two groups all had a small core infarction and a large mismatch of perfusion deficits before EVT, which is a representative of good collateral circulation.¹⁴ It is worth noting that the decrease in sICH caused by SBPr cannot offset the adverse prognosis brought about by SBPr. Therefore, it is particularly important to continue exploring the impact of BP changes on the perioperative pathophysiological mechanisms of EVT in acute ischaemic stroke.



Figure 2 Shape of the relationship between systolic blood pressure (SBP) reduction following successful reperfusion and outcomes. (A) 90-day outcome. (B) Symptomatic intracerebral haemorrhage.



Figure 3 Distribution of modified Rankin Scale (mRS) scores at 90 days (A) and the incidence of symptomatic intracerebral haemorrhage (sICH) (B) according to the categories of systolic blood pressure (SBP) reduction (SBPr).

Another important finding was that the association of SBPr with the 90-day outcome showed a significant interaction with the baseline ASPECT score. Recently, patients with large core infarction have been confirmed to be effective with EVT by increasing evidence.^{3 4} The results

	Subgroup	No. c	f Patients	SBPr	OR (95%CI)		Р	Pint	Subgroup	No. of	Patients	SBPr	OR (95%CI)		Р	Pint
	Hypertension history							0.653	Hypertension history							0.327
	No		317	410% 4.10% 10%-20% 20%-30%	1.56(0.351.7.123) 1.314(0.644.2.663) 1.185(0.539.2.606) 2.952(1.142.7.63)	ŧ	0.553 0.453 0.672		No		317	+10% +10% 10%-20% 20%-30% >30%	0.984(0.107.9.045) 1.005(0.365.2.768) 0.153(0.018.1.261) 0.896(0.221.3.841)	<u> </u>	0.989 0.992 0.081 0.878	
	Yes		591	410% 4-10% 10%-20% 20%-30%	0.814(0.257.2.578) 1.419(0.822.2.449) 1.037(0.603.1.782) 1.791(0.935.3.429)	ŧ	0.723 0.200 0.800 0.075		Yes		591	+10% +-10% 10%-20% 20%-30% +30%	1.747(0.419,7.290) 0.856(0.341,2.151) 0.648(0.248,1.607) 0.241(0.05,1.15)	-	0.444 0.741 0.377 0.074	
	Collateral circulation							0.976	Collateral circulation							0.092
	Poor		413	10% 10%-20% 20%-30%	0.936(0.256.3.423) 1.423(0.772.2.624) 1.114(0.601.2.065)	ŧ	0.92 0.73		Poor		413	#10% 10% 10%20% 20%30%	0.976(0.196,4,862) 0.81(0.365,1,734) 0.173(0.048,0.624)	÷	8.977 8.003	
	Good		492		2.161(0.941,4.964) 1.61(0.48,5.401) 1.518(0.817,2.823) 1.211(0.642,2.285) 2.257(1.1,4.628)	Ē	0.065		Good		492	1000	0.191(0.042,0.876) 3.375(0.496,22,965 1.443(0.3215,730) 1.815(0.235,730) 1.499(0.23,7,737)	-	0.033	
	Antihypertensive treatment							0.203	Antihypertensive treatment							0.698
	No		402	±19%					No	· .	402	±10%				
	Yes		505		1.22/00/47/04/27/50 1.22/500/69/1.2.342/ 0.77/6/0.40/1.1.56/6 2.657(1.148,6.151)	Ŧ	0.43 0.45 0.023		Yes		505		1,00000 279 8 618 1,00200 299 8 618 0,36200071 1,840 0,371(0.043,3,217)	-	0.369	
				10%-30% 20%-30%	1.503(0.809.2.921) 1.465(0.795.2.7) 1.875(0.927.3.789)	-	0.130					10%-20% 20%-30% >30%	1.84500.311 8.711 0.833(0.349,1.966) 0.478(0.181,1.261) 0.401(0.121,1.331)		0.68	
	ASPECT score							0.024	ASPECT score							0.751
	6-10		113	410% 4110% 10%-20% 20%-30% 130%	0.143(0.014.1.477) 0.701(0.157.3.127) 0.537(0.112.2.572) 0.742(0.093.5.936)	<u> </u>	0.100 0.641 0.433 0.775		5-5 6-10		113	410% 4-10% 10%-20% 20%-30% +30% 410%	4.187(0.217.80.669 2.204(0.243.20.02) 0.533(0.038,7.41) 0(0,0)	+	0.343 0.483 0.64 0.995	
				4-10% 10%-20% 20%-30% +30%	1.879(0.706.4.995) 1.679(1.066.2.67) 1.269(0.806.2.064) 2.348(1.342,4.107)	ŧ.	0.200					4-10% 10%-30% 20%-30%	1.416(0.367,5.467) 0.918(0.44,1.913) 0.489(0.207,1.156) 0.467(0.163,1.337)		0.614 0.818 0.103 0.155	
	Occlusion site							0.954	Occlusion site							0.976
	ICA		361	1000	1.24800.26.5.0511 1.18800.514.2.458 1.18800.514.2.458	<u> </u>	0.658		ICA		351	110% 10% 10%-30%	0.621(0.071.5.435) 0.694(0.314.2.55) 0.375(0.107.1.338) 0.418(0.104.1.676)	-	0.687 0.835 0.124 0.218	
	MCA M1		474		1789(0.487.8.443) 1881(0.487.8.443) 1813(0.714.2.413) 1861(0.947.2.063)	<u> </u>	0.374		MCA M1		474		4.029(0.833,19.48) 1.350(477,3.819) 0.750(22.2.556) 0.591(0.114,3.055)	Ē	0.043	
	MeVO		83	100,300	000.0) 0.85200.2.4.3451 0.57200.114.2.855 0.86530.112.8.128		0.995		MeVO		83	1100	878.00 87	;		
	BaselineSBP							0.872	BaselineSBP							0.031
	<140mmHg		317	410% 4.10% 10%-20% 20%-30%	1.174(0.479.2.88) 1.225(0.678.2.213) 1.076(0.25,4.636)	ŧ	0.726 0.500 0.922		<140mmHg		317	10% -10% 10%-20% 20%-30%	1.709(0.51,5.725) 0.47(0.149,1.481) 3.759(0.662,21.331)		0.385 0.197 0.135	
	≥140mmHg		591	#10% 4-10% 10%-20% 20%-30% +30%	1.301(0.51.3.318) 0.904(0.362.2.252) 1.678(0.641,4.394)	÷	0.582		≥140mmHg		591	#10% <-10% 10%-20% 20%-30% >30%	1.294(0.277.6.049) 0.436(0.087.2.189) 0.456(0.083.2.52)		0.744 0.313 0.368	
A						Colorina Colorina		В						Carlinou		

Figure 4 Relationship of levels of systolic blood pressure (SBP) following successful reperfusion according to different subgroups. (A) Relationship between SBP reduction (SBPr) and poor outcome; fully adjusted indicates ORs adjusted for age, sex, history of hypertension, diabetes mellitus, antihypertensive treatment, TOAST, baseline NIHSS and ASPECT, occlusion site and collateral circulation analysed using a multivariable logistic regression model. (B) Symptomatic intracerebral haemorrhage; adjusted for baseline NIHSS, ASPECT and collateral circulation. ASPECT, Alberta Stroke Programme Early CT; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke Treatment. of our study, however, did not find a correlation in these patients between SBPr and poor outcomes. Furthermore, according to the OR value, moderate BP reduction might have partial protective effects. Unfortunately, because of our small sample, the association was not statistically significant. Further trials targeting patients with large core infarctions may elucidate the role of moderate BP reduction.

To prevent reperfusion injury, antihypertensive treatment is very common in clinical practice after EVT. A recent study from South Korea shows that a medicationinduced BP decrease during the first 24 hours after successful EVT may be harmful for patients with acute ischaemic stroke.²⁷ Additionally, a subgroup analysis of the OPTIMAL-BP trial¹³ showed that in the conventional management group, the lower the mean 24-hour BP was, the better the outcome. Unexpectedly, in our study, the association between SBPr and poor outcomes was also found in the no-antihypertensive treatment group (spontaneous BP decreases). However, in the no-antihypertensive treatment group, we found that the relationship is only shown in populations with significant SBP drop (>30%). Moreover, a sensitive analysis for with or without antihypertensive treatment showed the similar results (online supplemental figure S1). Further research needs to be guaranteed.

The results of our study emphasise the complexity of managing BP after EVT. The main strength of this study was that it provides in-depth research on the impact of BP reduction on the prognosis after EVT. Furthermore, the subgroup analysis provides new insights for individualised BP management in patients with EVT. Nevertheless, several limitations need to be acknowledged in the study. First, due to inherent limitation of the retrospective design, the BP management protocols between different centres have not been uniformly formulated, and the emergency room antihypertensive treatment data was not obtained. However, we included the use of continuous intravenous antihypertensive treatment after EVT as an independent variable in the statistical analysis and further conducted a subgroup analysis. Second, we did not obtain detailed information on BP variability and intraoperative BP during the perioperative period of EVT, which have also been proven to be associated with functional outcomes after EVT. Third, we could not obtain the infarct volume to assess the relation between BP reduction and infarct extension, which could provide a potential mechanism leading to worse outcomes associated with BP reductions.

CONCLUSIONS

Among patients who received EVT due to LVOS in the anterior circulation, a significant drop in SBP might be related to a poor functional outcome and a reduced incidence of sICH. Several factors need to be considered in the periprocedural BP management, such as baseline ASPECT score. Our study provides new insights for individualised BP management. A further study with a prospective design investigating the optimisation of periprocedural BP management in EVT is needed.

Contributors XH, XD, ZZ and JX: study design. HW, JX, ZL and QY: data acquisition. ZL and QY image analysis. XH, XD and HW wrote the primary manuscript. ZZ and JX: critical revision. ZZ and JX are responsible for the overall content as guarantors.

Funding This work was supported by the Natural Science Research Projects in Anhui Universities (2022AH051244), the Scientific Research Fund Project for Talent Introduction of Yijishan Hospital, Wannan Medical College in China (No. YR202111, YR202210), the Health Research Program of Anhui in China (No. AHWJ2022b090), Key Research Project of Wannan Medical College (No. WK2023ZZD21), Wuhu Science and Technology Project (No. 2023JC28)..

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Yijishan Hospital of Wannan Medical College (2019-039).

Provenance and peer review Not commissioned; externally peer reviewed. **Data availability statement** Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Xianjun Huang http://orcid.org/0000-0003-2646-982X Qiankun Cai http://orcid.org/0000-0001-8725-1934

REFERENCES

- 1 Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet* 2016;387:1723–31.
- 2 Tao C, Nogueira RG, Zhu Y, et al. Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion. N Engl J Med 2022;387:1361–72.
- 3 Huo X, Ma G, Tong X, *et al.* Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct. *N Engl J Med* 2023;388:1272–83.
- 4 Sarraj A, Hassan AE, Abraham MG, et al. Trial of Endovascular Thrombectomy for Large Ischemic Strokes. N Engl J Med 2023;388:1259–71.
- 5 Rabinstein AA, Albers GW, Brinjikji W, *et al.* Factors that may contribute to poor outcome despite good reperfusion after acute endovascular stroke therapy. *Int J Stroke* 2019;14:23–31.

- 6 Bösel J. Optimal Blood Pressure for Stroke Thrombectomy: High Time for Prospective Data! *Stroke* 2019;50:2648–9.
- 7 Qureshi AI, Ezzeddine MA, Nasar A, et al. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med 2007;25:32–8.
- 8 Katsanos AH, Malhotra K, Ahmed N, *et al.* Blood Pressure After Endovascular Thrombectomy and Outcomes in Patients With Acute Ischemic Stroke: An Individual Patient Data Meta-analysis. *Neurology* (*ECronicon*) 2022;98:e291–301.
- 9 Mistry EA, Sucharew H, Mistry AM, et al. Blood Pressure after Endovascular Therapy for Ischemic Stroke (BEST): A Multicenter Prospective Cohort Study. Stroke 2019;50:3449–55.
- 10 Anadani M, Arthur AS, Tsivgoulis G, et al. Blood Pressure Goals and Clinical Outcomes after Successful Endovascular Therapy: A Multicenter Study. Ann Neurol 2020;87:830–9.
- 11 Mistry EA, Mayer SA, Khatri P. Blood Pressure Management after Mechanical Thrombectomy for Acute Ischemic Stroke: A Survey of the StrokeNet Sites. J Stroke Cerebrovasc Dis 2018;27:2474–8.
- 12 Ghozy S, Mortezaei A, Elfil M, et al. Intensive vs Conventional Blood Pressure Control After Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. JAMA Netw Open 2024;7:e240179.
- 13 Nam HS, Kim YD, Heo J, et al. Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial. JAMA 2023;330:832–42.
- 14 Yang P, Song L, Zhang Y, et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial. *Lancet* 2022;400:1585–96.
- 15 Mazighi M, Richard S, Lapergue B, et al. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial. *Lancet Neurol* 2021;20:265–74.
- 16 Anadani M, Arthur AS, Alawieh A, et al. Blood pressure reduction and outcome after endovascular therapy with successful reperfusion: a multicenter study. J Neurointerv Surg 2020;12:932–6.
- 17 Goyal M, Ospel JM, Menon BK, et al. MeVO: the next frontier? J NeuroIntervent Surg 2020;12:545–7.
- 18 Zaidat OO, Yoo AJ, Khatri P, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 2013;44:2650–63.
- 19 Tan IYL, Demchuk AM, Hopyan J, et al. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. AJNR Am J Neuroradiol 2009;30:525–31.
- 20 Hacke W, Kaste M, Bluhmki E, *et al.* Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 2008;359:1317–29.
- 21 Anadani M, Matusevicius M, Tsivgoulis G, et al. Magnitude of blood pressure change and clinical outcomes after thrombectomy in stroke caused by large artery occlusion. Eur J Neurol 2021;28:1922–30.
- 22 Anadani M, Maïer B, Escalard S, et al. Magnitude of Blood Pressure Change After Endovascular Therapy and Outcomes: Insight From the BP-TARGET Trial. Stroke 2022;53:719–27.
- 23 Mistry EA, Hart KW, Davis LT, *et al.* Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke. *JAMA* 2023;330:821.
- 24 Samuels N, van de Graaf RA, van den Berg CAL, et al. Blood Pressure During Endovascular Treatment Under Conscious Sedation or Local Anesthesia. *Neurology (ECronicon)* 2021;96:e171–81.
- 25 Castillo J, Leira R, García MM, et al. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. *Stroke* 2004;35:520–6.
- 26 Zhang Y, Jiang M, Gao Y, *et al.* "No-reflow" phenomenon in acute ischemic stroke. *J Cereb Blood Flow Metab* 2024;44:19–37.
- 27 Jung JW, Kim KH, Yun J, et al. Functional Outcomes Associated With Blood Pressure Decrease After Endovascular Thrombectomy. JAMA Netw Open 2024;7:e246878.